The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | What are the latest developments in KRAS-mutant NSCLC?
Joshua Sabari, MD, NYU Langone Health Perlmutter Cancer Center, New York, NY, comments on updates in the management of KRAS-mutant non-small cell lung cancer (NSCLC). Current KRAS inhibitors such as sotorasib and adagrasib are currently used for G12C mutations. Findings from the CodeBreak 200 trial (NCT04303780) demonstrated sotorasib to improve survival to docetaxel in KRAS G12C-mutatnt NSCLC, but was ineffective in KRAS G12D and G12V-mutant NSCLC. JDQ443 is additionally a novel KRAS inhibitor assessed in the KontRASt-01 trial (NCT04699188), and demonstrated promising efficacy with an encouraging safety profile. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
